FDA Broadens use of Xandi for Hormone Refractory PrCa

Xtandi Approved by FDA for Prostate Cancer Patients Before Chemo

FDA Approves Today

The drug Xtandi (enzalutamide) was FDA approved in 2012 for use in metastatic Castrate Resistant (or Hormone Refractory) prostate cancer patients AFTER they had been treated with chemotherapy.  But today, the FDA approved its use in these same patients BEFORE they have had chemo, creating one more important option for these men. Read Press Release Here.

Xtandi is a second line hormonal therapy, which can suppress testosterone at 3 different sources, giving many men an additional cancer response after failing initial hormone therapy.

Read more about Xtandi in this PCRInsights article by Dr Neal Shore - XTANDI (enzalutamide): A New Treatment for Metastatic Castration-Resistant Prostate Cancer

Read more from Dr Mark Scholz's Feb 2014 blog - Xtandi (enzalutamide), the Star of the 10th Annual Genitourinary Meeting

Also, Watch Dr Charles 'Snuffy' Myers' short videos on Xtandi - Xtandi + Phase 3 Prevail Trial Xtandi + PCa Remissions

For discussion with your physician(s), make sure you have a basic understanding of your personal cancer status.  A researched question is a better question:

1) Are you "Castrate Resistant" (or Hormone Refractory)? 2) Do you have "Metastatsis"? 

For more assistance, contact the PCRI Helpline at Help@PCRI.org

Xtandi (enzalutamide) is a prescription pill.  It is usually prescribed as 4 pills taken together, once a day.  Discuss with your pharmacist, and your physician(s).

Copyright © 2014 Prostate Cancer Research Institute, All rights reserved. You are receiving this email because you subscribed to our newsletter on our website.

Our mailing address is:

Prostate Cancer Research Institute

5777 West Century Blvd,
Suite 800

Los Angeles, CA 90045